High Growth Tech Stocks To Watch In November 2025

As global markets navigate a complex landscape marked by a record U.S. government shutdown and heightened scrutiny on AI spending, the technology-heavy Nasdaq Composite has led major indexes lower, reflecting broader concerns about elevated valuations in growth-oriented stocks. In this environment, identifying high-growth tech stocks requires careful consideration of their potential to innovate and adapt amidst economic uncertainties and shifting investor sentiment.

Top 10 High Growth Tech Companies Globally

Name Revenue Growth Earnings Growth Growth Rating Giant Network Group 34.13% 39.54% ★★★★★★ Shengyi TechnologyLtd 21.50% 32.87% ★★★★★★ Zhongji Innolight 30.75% 31.56% ★★★★★★ Pharma Mar 26.56% 44.88% ★★★★★★ Hacksaw 32.71% 37.88% ★★★★★★ Gold Circuit Electronics 26.64% 35.16% ★★★★★★ eWeLLLtd 25.02% 24.93% ★★★★★★ KebNi 24.89% 61.24% ★★★★★★ CD Projekt 35.69% 51.01% ★★★★★★ CARsgen Therapeutics Holdings 100.40% 118.16% ★★★★★★

Click here to see the full list of 243 stocks from our Global High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

BioGaia

Simply Wall St Growth Rating: ★★★★★☆

Overview: BioGaia AB (publ) is a healthcare company that develops, manufactures, markets, and sells probiotic products for gut, oral, and immune health across various regions including Europe and the United States, with a market cap of approximately SEK9.96 billion.

Operations: BioGaia generates revenue primarily from its Pediatrics segment, contributing SEK1.09 billion, and the Adult Health segment with SEK357.59 million.

BioGaia's recent strides in probiotic research and product innovation underscore its potential within the high-growth tech segment of health-focused biotechnologies. The company's revenue is expected to grow annually by 10.8%, outpacing the Swedish market's 3.8%. Moreover, earnings are forecasted to surge by 21.9% annually, significantly above the market average of 12.7%. This growth trajectory is bolstered by groundbreaking discoveries like identifying gut bacteria that produce serotonin, potentially revolutionizing treatments for disorders like IBS and enhancing gastrointestinal health. Additionally, BioGaia’s strategic expansion into direct markets in Germany and Austria aligns with its robust growth strategy, further solidifying its standing in the biotech industry.

Navigate through the intricacies of BioGaia with our comprehensive health report here. Examine BioGaia's past performance report to understand how it has performed in the past.OM:BIOG B Earnings and Revenue Growth as at Nov 2025

Kohoku KogyoLTD

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kohoku Kogyo CO., LTD. specializes in manufacturing and selling lead terminals for aluminum electrolytic capacitors, optical components for fiber communication networks, and precision quartz glass components across various international markets, with a market cap of ¥85.23 billion.

繼續閱讀

Operations: The company generates revenue through the production and sale of lead terminals, optical components for fiber networks, and precision quartz glass components. It operates across Japan, China, other parts of Asia, England, the U.S., and various international markets.

Kohoku Kogyo's recent performance and strategic moves position it intriguingly within the technology sector. With an earnings growth of 23.9% annually, significantly outstripping Japan's market average of 7.9%, the company is demonstrating robust financial health. This growth is complemented by a revenue increase forecasted at 11.9% per year, well above the national rate of 4.5%. Notably, their R&D commitment has fostered innovations that keep them competitive in the electronics industry where they recently reported a notable earnings growth of 15.7% over the past year, surpassing industry growth rates by more than double. These figures underscore Kohoku Kogyo’s potential to sustain its upward trajectory amidst volatile market conditions and a highly competitive tech landscape.

Click here and access our complete health analysis report to understand the dynamics of Kohoku KogyoLTD. Gain insights into Kohoku KogyoLTD's historical performance by reviewing our past performance report.TSE:6524 Earnings and Revenue Growth as at Nov 2025

Vitalhub

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vitalhub Corp. develops technology and software solutions for health and human service providers across several regions, including Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally, with a market cap of CA$644.12 million.

Operations: Vitalhub offers technology and software solutions tailored for health and human service providers in various regions. The company operates with a market cap of CA$644.12 million, focusing on delivering innovative products to enhance service delivery in healthcare sectors globally.

Vitalhub's recent financial trajectory illustrates a blend of challenges and growth, marked by a significant revenue jump to CAD 77.58 million from CAD 48 million year-over-year, despite a slight dip in net income from CAD 2.21 million to CAD 2.04 million. This performance is underpinned by an aggressive R&D strategy, crucial for staying competitive in the tech-driven healthcare sector where innovation leads market trends. The company's recent follow-on equity offering of CAD 65 million also suggests a strategic reinvestment into its core operations, aiming to capitalize on emerging technological advancements and expand its market footprint further.

Take a closer look at Vitalhub's potential here in our health report. Explore historical data to track Vitalhub's performance over time in our Past section.TSX:VHI Earnings and Revenue Growth as at Nov 2025

Where To Now?

Investigate our full lineup of 243 Global High Growth Tech and AI Stocks right here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Ready For A Different Approach?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OM:BIOG B TSE:6524 and TSX:VHI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

查看留言